FGF21 and Hepatic steatosis: Studies have shown that FGF21 gene therapy reduces body weight, adipose tissue hypertrophy and inflammation, and hepatic steatosis, and improves insulin sensitivity, with sustained effects present for over 1 year in obese mice (21, 22).